Goldman Sachs Raises Everest Medicines’ Target Price to HK$48.32 on Stronger Commercial and R&D Outlook
Goldman Sachs’ latest report on China’s biotechnology sector highlights Everest Medicines (HKG: 1952) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is…